Rx-360 recently conducted elections for the new Board of Directors and is pleased to announce that, effective immediately, the following individuals are taking on a leadership role with the organization. Congratulations to the newly elected board members:
Board of Directors
Lynne Byers (GSK), Chair, effective January 1, 2011
Al Kentrup (Pfizer), Vice-Chair, effective January 1, 2011
3 year Term
• Matt Anderson (Baxter)
• Tom Beil (Sigma Aldrich)
• Janice Berger (AstraZeneca)
• Thomas Crispin (Bayer)
• Natalie Garrett (Abbott)
• Al Kentrup (Pfizer)
• Martin VanTrieste (Amgen)
• Guy Villax (Hovione)
2 year Term
• Jack Brinnier (Watson)
• Lynne Byers (GSK)
• Burghard Frieberg (Merck KGaA)
• Diane Petitti (Amylin)
• Nick Shackley (BASF)
• Paul Smaltz (Mallinckrodt Baker)
• Andreas Wirth (Novartis)
1 year Term
• Heike Falkenhagen (Boehringer Ingelheim)
• Chris Franco (Takeda)
• David Haggard (Merck)
• Ernie Kelly (Cephalon)
• Melissa Seymour (Biogen Idec)